Specifically, we aimed to examine whether patients with MS displayed overrepresentations in the following genetic markers: FV Leiden polymorphism, FV R2, Prothrombin 20210 G>A, FXIII Val34Leu, beta-fibrinogen −455 G>A, HPA1a/1b, MTHFR 677 C>T, MTHFR 1298 A>T, PAI-1 4G/5G, ACE I/D, and Apo B R3500Q compared with healthy individuals. This evidence concerns the gene FGB and myeloid sarcoma.